HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pütz, M. M. Articles by Smith, G. L. Search for Related Content PubMed PubMed Citation Articles by Pütz, M. M. Articles by Smith, G. L. Agricola Articles by Pütz, M. M. Articles by Smith, G. L.

Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy

¹ Department of Virology, Faculty of Medicine, Imperial College London, St Mary's Campus, London W2 1PG, UK
² Department of Physiopathology, Experimental Medicine and Public Health, University of Siena, Via A. Moro, 53100 Siena, Italy

Correspondence
Geoffrey L. Smith
glsmith{at}imperial.ac.uk

Decades after smallpox was eradicated and vaccination discontinued, the level of residual immunity in today's population is largely unknown. This study describes an epidemiological assessment in Italians of antibodies against the intracellular mature virus (IMV) and extracellular envelope virus (EEV) forms of Vaccinia virus. Serum samples (n=642) were taken in 1993 and 2003 from people between 11 and 102 years old. Most citizens >27 years old were positive for antibodies to IMV and EEV. These antibodies were long-lasting and similar titres were present in citizens between 30 and 100 years old. Serum samples from 1993 and 2003 displayed very similar EEV- and IMV-specific antibody titres. By using these data and demographic considerations, it was predicted that, in 2003, 46 % of the Italian population were positive for both IMV and EEV, 42 % were negative for both and 12 % were positive for one antigen.

This article has been cited by other articles:

				M. R.-E.-I. Benhnia, M. M. McCausland, J. Moyron, J. Laudenslager, S. Granger, S. Rickert, L. Koriazova, R. Kubo, S. Kato, and S. Crotty Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement J. Virol., February 1, 2009; 83(3): 1201 - 1215. [Abstract] [Full Text] [PDF]

				C. M. Midgley, M. M. Putz, J. N. Weber, and G. L. Smith Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax J. Gen. Virol., December 1, 2008; 89(12): 2992 - 2997. [Abstract] [Full Text] [PDF]

				L. Jing, D. H. Davies, T. M. Chong, S. Chun, C. L. McClurkan, J. Huang, B. T. Story, D. M. Molina, S. Hirst, P. L. Felgner, et al. An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling J. Virol., July 15, 2008; 82(14): 7120 - 7134. [Abstract] [Full Text] [PDF]

				A. D. Garcia, C. A. Meseda, A. E. Mayer, A. Kumar, M. Merchlinsky, and J. P. Weir Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines Clin. Vaccine Immunol., August 1, 2007; 14(8): 1032 - 1044. [Abstract] [Full Text] [PDF]

				N. Jacobs, R. A.-J. Chen, C. Gubser, P. Najarro, and G. L. Smith Intradermal immune response after infection with Vaccinia virus. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1157 - 1161. [Abstract] [Full Text] [PDF]

				M. Law, G. C. Carter, K. L. Roberts, M. Hollinshead, and G. L. Smith From the Cover: Ligand-induced and nonfusogenic dissolution of a viral membrane PNAS, April 11, 2006; 103(15): 5989 - 5994. [Abstract] [Full Text] [PDF]